Smart drug delivers chemo directly to HER2 breast cancer cells
NCT ID NCT06115902
First seen Jul 08, 2026 · Last updated Jul 09, 2026 · Updated 1 time
Summary
This trial tests an experimental drug called TQB2102 for people with HER2-positive breast cancer that has returned or spread to other parts of the body. TQB2102 is an antibody-drug conjugate—a targeted therapy that binds to HER2 on cancer cells and releases a potent chemotherapy directly inside them. The study aims to see if the drug can shrink tumors and how safe it is. Participants must have HER2-expressing breast cancer that is not curable with surgery or radiation.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- TQB2102 (antibody-drug conjugate targeting HER2)
- What this could lead to
- If successful, TQB2102 could offer a new treatment option for people with HER2-positive breast cancer that has returned or spread.
- What could go wrong
- This is an early-phase trial, so the drug may not shrink tumors or may cause side effects. It is too soon to know if it will be better than existing therapies.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Anhui Pronvincial Cancer Hospital
Hefei, Anhui, 230000, China
-
Cancer Hospital Affiliated to Shandong First Medical University
Jinan, Shandong, 250117, China
-
Cancer Hospital Chinese Academy of Medical Science
Beijing, Beijing Municipality, 100021, China
-
Chongqing University Cancer Hospital
Chongqing, Chongqing Municipality, 400030, China
-
Ganzhou People's Hospital
Ganzhou, Jiangxi, 341000, China
-
Guangxi Medical University Cancer Hospital
Nanning, Guangxi, 530021, China
-
Harbin Medical University Cancer Hospital
Harbin, Heilongjiang, 150081, China
-
Hunan Cancer Hospital
Changsha, Hunan, 410031, China
-
Jiangmen Central Hospital
Jiangmen, Guangdong, 529000, China
-
Jilin Cancer Hospital
Changchun, Jilin, 130012, China
-
Liaoning Cancer Hospital & Institute
Shenyang, Liaoning, 110000, China
-
Linyi Cancer Hospital
Linyi, Shandong, 276034, China
-
Lu'an People's Hospital
Lu'an, Anhui, 237008, China
-
Shanxi Cancer Hospital
Taiyuan, Shanxi, 030000, China
-
Suining Central Hospital
Suining, Sichuan, 629000, China
-
Sun Yat-Sen University Cancer Center
Guangzhou, Guangdong, 510060, China
-
The First Affiliated Hospital of Xi'an Jiaotong University School of Medicine
Xi'an, Shannxi, 710089, China
-
The First Hospital of China Medical University
Shenyang, Liaoning, 110001, China
-
Tianjin Medical University Cancer Institute & Hospital
Tianjin, Tianjin Municipality, 300202, China
-
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, 310022, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a radioactive tracer pinpoint Cancer's first stop?
- Can a personalized exercise program boost recovery in cancer survivors?
- Smartwatch could spot nerve damage before it starts
- Could ionized gas help fight breast cancer after surgery?
- Radiation may let breast cancer patients keep their nipple
- Can a smart digital program restore sleep for cancer survivors?